Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscription Services
Promote Your Event
Submission Forms
Place an Ad
Weather
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Items For Sale
Jobs
Pets
Auctions, Estate & Garage Sales
Place an ad
Services
Community
Personals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Centogene N.V.
(NQ:
CNTG
)
1.140
+0.040 (+3.64%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Centogene N.V.
< Previous
1
2
Next >
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Reports First Half 2023 Financial Results
September 07, 2023
Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
September 01, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
August 31, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in August
August 07, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
July 14, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
July 12, 2023
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting
June 30, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment
June 27, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
June 14, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Reports Full Year 2022 Financial Results
May 16, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in May
May 05, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notice
April 28, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline
April 26, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in April
April 14, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases
April 12, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
April 11, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma
March 09, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in March
March 08, 2023
From
Centogene NV
Via
GlobeNewswire
In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD)
February 21, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
February 07, 2023
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
February 07, 2023
From
Centogene NV
Via
GlobeNewswire
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
January 10, 2023
From
Twist Bioscience Corporation
Via
Business Wire
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
January 09, 2023
Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD)
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
December 28, 2022
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results
December 22, 2022
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Receives Nasdaq Non-Compliance Notice
December 16, 2022
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in December
December 01, 2022
From
Centogene NV
Via
GlobeNewswire
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
November 21, 2022
Adding significant financial expertise with an impressive track record in value creation
From
Centogene NV
Via
GlobeNewswire
CENTOGENE to Participate in Upcoming Conferences in November
November 10, 2022
From
Centogene NV
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.